Core Insights - BillionToOne, Inc. completed an upsized IPO of 5.23 million shares at $60 each, raising approximately $314 million [1] - The company specializes in molecular diagnostics, focusing on prenatal genetics and oncology, utilizing its patented Quantitative Counting Templates (QCT) platform [1] Company Performance - Analysts express strong confidence in BillionToOne's growth potential, citing a robust appetite for high-growth, profitable diagnostic companies [2] - The UNITY test positions the company well in the $2.5 billion U.S. prenatal market, with expectations for continued growth driven by expanded sales reach and greater test awareness [3] - BLLN stock has seen a significant increase of 113% since its IPO, trading at 18 times projected 2026 revenue [4] Analyst Ratings - Stifel has a Buy rating with a price target of $145 [6] - Wells Fargo has an Equal-Weight rating with a price target of $110 [6] - JPMorgan has an Overweight rating with a price target of $150 [6] - Jefferies has a Hold rating with a price target of $117 [6] - BTIG has a Buy rating with a price target of $160 [6]
Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally